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Background: Anti-angiogenesis is a validated strategy to treat cancer, with efficacy in controlling both primary
tumor growth and metastasis. The role of the Notch family of proteins in tumor angiogenesis is still emerging, but
recent data suggest that Notch signaling may function in the physiologic response to loss of VEGF signaling, and
thus participate in tumor adaptation to VEGF inhibitors.
Methods: We asked whether combining Notch and VEGF blockade would enhance suppression of tumor
angiogenesis and growth, using the NGP neuroblastoma model. NGP tumors were engineered to express a Notch1
decoy construct, which restricts Notch signaling, and then treated with either the anti-VEGF antibody bevacizumab
or vehicle.
Results: Combining Notch and VEGF blockade led to blood vessel regression, increasing endothelial cell apoptosis
and disrupting pericyte coverage of endothelial cells. Combined Notch and VEGF blockade did not affect tumor
weight, but did additively reduce tumor viability.
Conclusions: Our results indicate that Notch and VEGF pathways play distinct but complementary roles in tumor
angiogenesis, and show that concurrent blockade disrupts primary tumor vasculature and viability further than
inhibition of either pathway alone.
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The anti-vascular endothelial growth factor (VEGF) anti-
body bevacizumab (BV) is clinically validated to treat
human cancers in adults, and is currently being evalu-
ated as a therapy for pediatric tumors, including neuro-
blastoma [1]. However, it appears that essentially all
patients, even those who respond to BV initially, will ul-
timately progress despite ongoing treatment. Thus, a
similar limitation is anticipated in children treated with
this agent. The mechanisms of tumor progression during
BV treatment are not well understood.* Correspondence: dy39@columbia.edu
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distribution, and reproduction in any mediumWe have previously shown that VEGF inhibition dis-
rupts the blood vessels of the neuroblastoma NGP xeno-
graft model, but resistance occurs [2-4]. VEGF blockade
can increase cooption of existing vascular structures by
encroaching tumors [2], a mechanism which may partly
compensate for defective VEGF signaling. An additional
mechanism for tumor progression during VEGF block-
ade could be the activation of an alternative angiogenic
pathway. In support of this concept, we have shown that
the Notch pathway is up-regulated in neuroblastoma
when the VEGF receptor 2 (VEGFR2) is blocked with
the anti-VEGFR2 antibody DC101 [3].
To examine the role of Notch in tumor angiogenesis,
we have used the Notch1 decoy (N1D), a soluble con-
struct derived from the extracellular domain of the
Notch1 receptor that blocks Notch activation by seques-
tering Notch ligands [5]. Notch blockade using the N1D
disrupts tumor vasculature and decreases tumor viabilitytral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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that blocking the Notch and VEGF pathways simultan-
eously would disrupt the vasculature and inhibit tumor
growth more effectively than either agent alone. To test
this hypothesis, we evaluated the effects of expressing
N1D in combination with bevacizumab (BV) in the NGP
neuroblastoma xenograft model. Here, we report that
combining N1D with BV had a profound effect on the
tumor viability and the vasculature of NGP xenografts.
N1D and BV additively increased tumor endothelial cell
apoptosis, leading to blood vessel regression, and cell
death.Methods
Transfections and cell culture
NGP-LacZ and NGP-N1D cells were maintained as de-
scribed [5]. pLKO.1 empty vector (control) and pLKO.1
Notch1 shRNA (Notch1 KD) plasmids (Sigma Aldrich)
were stably transfected into NGP cells, selected and
maintained in 1 mg/ml puromycin (Sigma Aldrich).NGP xenograft model
1 × 106 cells were injected intrarenally into 4–6 week
old NCR female nude mice (Taconic, Germantown, NY)
as previously described [3]. All animal experiments were
approved by the Columbia University Institutional Ani-
mal Care and Use Committee. At sacrifice, organs were
harvested and weighed as previously described [3].Bevacizumab and placebo administration
NGP-LacZ and NGP-Notch1 decoy (N1D) tumor-
bearing mice were randomized one week after implant-
ation. At this time, 28 mice in each group were treated
with 100 μg mouse albumin (Sigma Aldrich) (placebo),
and another 28 with 250 μg bevacizumab (10 mg/kg BV,
Genentech) by intraperitoneal injection biweekly until
time of sacrifice. Both the N1D and BV are fused to a hu-
man Fc fragment. Immunohistochemistry (Additional file 1:
Figure S1A) and SDS-PAGE (Additional file 1: Figure S1B)
to human Fc was performed on tumors, and confirmed
expression of N1D in the tumors at time of sacrifice. Since
BV is also fused to human Fc, it could also be detected
in the NGP-LacZ + BV and NGP-N1D+BV tumors by
SDS-PAGE (Additional file 1: Figure S1B, lower band).Reagents
Primary antibodies: αSMA (Lab vision), cleaved Notch1
(Cell Signaling), PECAM-1 (Angioproteomie), Notch1
(Upstate), collagen IV (Cosmobio), biotinylated hFc
(Jackson Labs). Alexafluor probes (Invitrogen) were used
for fluorescent stains.Hypoxyprobe and quantification
Thirty minutes prior to sacrifice, mice received an intrape-
ritoneal injection of 0.1 ml of pimonidazole (Hypoxyprobe®,
Chemicon), and paraffin sections were used to stain for
pimonidazole with MAB-1 (Chemicon), following the ma-
nufacturer’s instructions. Four tumors per treatment group
were quantified, with an average of 10 images taken from
each tumor section at 20×. The images were then analyzed
using Adobe Photoshop using an arbitrary threshold
applied to all images.
Lectin perfusion and quantification
An intracardiac injection of 100 μl of Fluorescein labeled
Lycopersicon esculentum (Vector Labs) was delivered
2 minutes prior to 1% PFA and PBS perfusion, followed
by tumor collection. Tumors were fixed in 4% PFA and
50 μm thick sections were analyzed using confocal
microscopy.
TUNEL assay quantification
TUNEL staining and quantification was performed as
described [5]. An average of 20 images from each tumor
section, and 5 tumors per group were analyzed.
Collagen IV, PECAM-1 and EC apoptosis quantifications
Fresh-frozen, serial sections were used for Collagen IV,
PECAM-1 and EC apoptosis quantifications. Viable tumor
areas immunostained for collagen IV or PECAM-1 were
photographed at 10× (Collagen IV) or 20× (PECAM-1).
An average of 15 (Collagen IV) or 30 (PECAM-1) images
per tumor, and three tumors per group were analyzed.
For EC quantification, TUNEL, PECAM-1, stained sec-
tions were mounted with DAPI (Vector) and images
obtained at 40× magnification.
Cooption quantification
5 μm sections of paraffin-embedded livers or kidneys
were stained with hematoxylin and eosin (H&E). Tumor
sections were scanned using an Epson 4870 Scanner.
Glomeruli surrounded by at least one layer of tumor
cells were counted as coopted vasculature. One section
per tumor, and 28–30 tumors per group were analyzed.
VEGF ELISA
3 × 106 NGP-LacZ or NGP-N1D cells were plated on a
10 cm dish, and cultured in 6 ml of serum-free EBM-2
(Invitrogen) for 48 hrs. Supernatant from three indepen-
dent collections was measured, using a human VEGF
ELISA kit (R&D) following the manufacturer’s instructions.
HUVEC cell death and BrdU incorporation assays
8,000 HUVEC per well (48 well plate) were seeded on a
fibrinogen gel (Sigma), in basal EBM-2 media (Lonza).
Two hrs later, media was replaced by conditioned media
Hernandez et al. Vascular Cell 2013, 5:17 Page 3 of 14
http://www.vascularcell.com/content/5/1/17(CM) from NGP-LacZ or NGP-N1D cells (3×106 cells
per 10 cm2 plate, cultured for 24 hrs in EBM-2 basal
media. We added 50 ng/ml BV or 20 ng/ml rhVEGF165
(R&D) to the CM. For BrdU assays, 2 μl BrdU (Millipore)
was added per ml of CM. Cell death assays (Roche) or
BrdU incorporation assays (Millipore) were measured
23 hrs later, following the manufacturer’s instructions.
Immunoprecipitation and Western Blots
Tumors were lysed in a ratio of 100 ml of lysis buffer to
10 mg of tumor. 100 μl of tumor lysate was immunopreci-
pitated with A/G agarose beads (Santa Cruz Biotechnology)
and blotted with anti-human Fc (Pierce).
Reverse transcription and quantitative PCR
RNA was extracted from cells following the manufac-
turer’s instructions (Qiagen). Tissue RNA extraction was
performed with Ambion ToTALLY RNA kit (Ambion)
following the manufacturer’s specifications. RNA from
tissue or cells was reverse transcribed following the
manufacturer’s instructions (Invitrogen, DNAseI and
Superscript). Quantitative PCR was performed with the
Taqman system (Applied Biosystems) following the ma-
nufacturer’s specifications, using primers designed not to
amplify genomic DNA. GeNorm was used to select the
normalization values out of 6 housekeeping genes.
Microarrays and probes preparation
HG-U133A 2.0 (human genome) Gene Chips (Affymetrix,
Santa Clara, CA) were used to investigate gene expression
in xenograft tumors. The cRNA probes were synthesized
as recommended by Affymetrix, purified using RNeasy
and fragmented according to the Affymetrix protocol, and
15 μg of biotinylated cRNA were hybridized to the
microarrays. The samples were scanned with Affymetrix
Gene Chip Scanner 3000. The data set, corresponding to
24 tumors (6 arrays per group), has been deposited in
NCBI’s Gene Expression Omnibus (GEO) and is available
through accession number GSE (pending). Data were
RMA normalized using the Bioconductor open source
software.
Statistical analysis
Statistical analysis was performed using the Prism 5 soft-
ware (GraphPad Software, Inc. La Jolla, CA). One-way
analysis of variance was performed with post-hoc analysis
by Tukey’s Multiple Comparison Test. Graphs represent
mean and standard deviation in all cases.
Results
Combined blockade of notch and VEGF increases necrosis
and apoptosis in primary tumors
We have previously shown that inhibiting Notch signa-
ling with the soluble Notch1 decoy (N1D) decreasedviability (but not tumor weight), disrupted vasculature,
disorganized the interaction of endothelial cells with
pericytes in neuroblastoma NGP xenografts [5]. Given
the critical role of VEGF in tumor angiogenesis, we hy-
pothesized that combining Notch inhibition with VEGF
blockade would synergistically inhibit tumor growth and
angiogenesis. NGP-N1D cells or control NGP-LacZ cells
were implanted into the left kidney of athymic mice.
The mice were then randomized to treatment with ei-
ther placebo or BV, and sacrificed at 5.5 weeks. Consis-
tent with our previous data [5], there was no difference
in tumor weight between control NGP-LacZ and NGP-
N1D (Figure 1A). VEGF blockade with BV, however,
reduced NGP mean tumor weight by 61% (p < 0.001)
compared to NGP-LacZ. Combined treatment with
N1D and BV (NGP-N1D + BV), reduced mean tumor
weight by a similar extent, 60%, as compared to NGP-
LacZ, (p < 0.001).
Although there was no difference in tumor weight as
compared with BV treatment alone, the NGP-N1D + BV
tumors were noticeably more necrotic (Figure 1B),
which was confirmed by quantification of necrosis in
H&E sections (Figure 1C). Trichrome staining confirmed
that these differences were due to necrosis and not fi-
brosis (data not shown). When assessed by TUNEL, the
NGP-N1D + BV tumors exhibited significantly more
apoptosis then NGP-LacZ controls (14.4 fold), BV alone
(3.6 fold), or N1D alone (2.5 fold) (Figure 1D). Blockade
of Notch or VEGF did not have a direct effect on tumor
cell proliferation, as there was no difference in phospho-
histone H3 positive cells in areas of viable tumor
(Figure 1E). These data indicate that combined Notch
and VEGF blockade additively decreases tumor viability.
Combined blockade of notch and VEGF markedly
decreases perfusion
We next evaluated the effect of Notch and VEGF block-
ade on lectin perfusion (Figure 2A,B). We found that
with combined blockade (NGP-N1D + BV), there was a
paucity of vessels, with a significantly reduced (P < 0.05)
lectin-positive area (16% of control NGP-LacZ, Figure 2B).
Blockade with N1D or BV alone did not reduce overall
perfusion as measured by lectin-positive area (Figure 2B).
However, in the case of BV, bound lectin outlined
predominantly larger vessels (Figure 2A, arrow), or
coopted renal glomeruli (Figure 2A, arrowhead), which
contribute disproportionally to the total lectin-positive
area. There was a marked reduction in vessel branching
when VEGF was blocked (Figure 2C), either with BV
alone (12%) or with N1D + BV (7%), indicating that
VEGF blockade inhibits the small sprouts that initiate
neoangiogenesis.
The decrease in lectin-positive area for NGP-N1D+BV
relative to NGP-BV tumors suggested that there could be a
Figure 1 Combined Notch and VEGF increases tumor necrosis and apoptosis. (A) NGP-N1D tumors did not have different tumor weights
than NGP-LacZ controls. BV treatment reduced tumor weights compared to controls and NGP-Notch1 decoy. Combining Notch1 decoy with BV
reduced tumor weights compared to NGP-LacZ controls and NGP-N1D Error bars represent SD. ***P < 0.001. (B) NGP-N1D + BV tumors had
increased necrosis as seen by H&E. Bar = 400 μm. (C) Quantification of necrosis showed NGP-N1D + BV with increased necrosis. Error bars
represent SD. **P < 0.01, ***P < 0.001. (D) NGP-N1D and NGP-LacZ + BV tumors had increased numbers of TUNEL positive counts per field
compared to NGP-LacZ controls. An additive increase was observed in NGP-N1D+ BV tumors (p < 0.001). Error bars represent SD. *P < 0.05, **P < 0.01,
***P < 0.001. (E) Proliferation in tumors was assessed by phosphorylated-Histone H3 (H3-P) IHC. There was no significant difference in proliferation.
Error bars represent SD. P = n.s.
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fied coopted vessels by counting the number of glomeruli
surrounded by tumor cells in H&E sections (Figure 2D,
arrows). The number of coopted glomeruli in NGP-LacZ +
BV tumors was increased 2.3 fold compared to NGP-LacZ
tumors (Figure 2E). Notch blockade significantly attenu-
ated this BV-induced increase in cooption, with NGP-
N1D + BV tumors having significantly fewer coopted
glomeruli as compared to the NGP-LacZ + BV group
(115 vs 178, respectively, Figure 2E). These findings sug-
gest that Notch blockade attenuates BV-inducedcooption in NGP xenografts. Furthermore, immuno-
staining for cleaved Notch1, reflecting processing of the
Notch receptor after ligand binding, showed increased
activated Notch1 in coopted glomeruli as a result of BV
treatment in NGP tumors (Additional file 2: Figure S2).
These data implicate Notch signaling in BV-induced
cooption of host vasculature.
Blockade of VEGF results in tumor hypoxia
The lectin perfusion results demonstrate that combined
Notch and VEGF blockade reduces both neoangiogenesis
Figure 2 Combined Notch and VEGF blockade decreases perfusion and branching. (A) Lectin perfusion showed marked reduction in
perfusion in NGP-N1D + BV. Bar = 200 μm. (B) Lectin perfusion showed marked reduction in perfusion in NGP-N1D + BV. Error bars represent SD.
*P < 0.05. (C) Marked decrease in branches in NGP-LacZ + BV and NGP-N1D + BV. Error bars represent SD. *P < 0.05. (D) Representative H&E of
NGP-LacZ + BV and NGP-N1D + BV tumors with coopted glomeruli (black arrowheads). Bar = 100 μm. (E) Compared to NGP-LacZ controls,
NGP-LacZ + BV tumors had a higher number of coopted glomeruli per square inch. NGP-N1D tumors were not different from NGP-LacZ
controls. NGP-N1D + BV tumors had less coopted glomeruli than NGP-LacZ + BV tumors. Error bars represent SD. *P < 0.05, ***P < 0.001.
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mine if this resulted in increased hypoxia, we quantified
pimonidazole (Hypoxyprobe®) by IHC. There was signifi-
cantly more hypoxia in NGP-LacZ + BV (P < 0.05) and
NGP-N1D + BV (P < 0.001) as compared to NGP-LacZ.
(Figure 3A,B). NGP-N1D was not significantly different
from NGP-LacZ tumors.
We also quantified the expression of two hypoxia re-
sponsive genes, VEGF and PlGF, in the tumors by real-
time PCR. VEGF expression was significantly increased 3.1
fold (P < 0.01) in NGP-LacZ + BV and by 2.7 fold (P < 0.01)
in NGP-N1D + BV tumors compared to NGP-LacZ con-
trols and to NGP-N1D (Figure 3C). PlGF expression
behaved in a similar pattern: relative to NGP-LacZ
controls, NGP-N1D tumors had no change, while
NGP-LacZ + BV tumors had 4.7 fold more (p < 0.001),and NGP-N1D + BV tumors had 3.79 fold more PlGF
than controls (p < 0.001).
We further analyzed the tumors by gene expression
profiling using HG-U133A 2.0 (human genome) Gene
Chips (Affymetrix). VEGF expression was increased 2.36
fold in NGP-LacZ + BV and 2.56 fold in NGP-N1D + BV
tumors (see Additional file 3 for significantly increased
genes). Gene Set Enrichment Analysis (GSEA) [6] demon-
strated that VEGF blockade resulted in enrichment of
hypoxia related gene sets in comparison to control NGP-
LacZ tumors (Table 1, Figure 3D). For NGP-N1D+ BV
there were 7 hypoxia related gene sets that were enriched
(3 positively, 4 negatively); for NGP-LacZ + BV there
were 3 hypoxia related gene sets that were enriched
(3 positively); but none for NGP-N1D. Comparing
NGP-LacZ + BV to NGP-N1D + BV did not show any
Figure 3 Blockade of VEGF increases tumor hypoxia. (A) Immunostaining for pimonidazole hypoxyprobe shows that NGP-LacZ controls (top
left) show almost no detectable staining. Both NGP-N1D and NGP-LacZ + BV (top right and bottom left) show increased areas of Hypoxyprobe in
some areas of the tumor, but wide areas remained well oxygenated. NGP-N1D + BV tumors (bottom right) show Hypoxyprobe staining
throughout the tumor. Bar = 400 μm. (B) Quantification of Hypoxyprobe staining showed increased the hypoxia of NGP-LacZ + BV and NGP-N1D + BV
compared to NGP-LacZ controls. Error bars represent SD. *P < 0.05, **P < 0.001. (C) VEGF expression was increased in NGP-LacZ + BV and NGP-N1D + BV
compared to NGP-LacZ or NGP-N1D. Error bars represent SD. **P < 0.01, ***P < 0.001. (D) GSEA enrichment plots are shown for HARRIS_HYPOXIA gene
set NGP-N1D + BV vs NGP-LacZ, and for SEMENZA_HIF1_TARGETS NGP-LacZ + BV vs NGP-LacZ. Normalized Enrichment Score (NES) and False
discovery rated (FDR) q-values are shown.
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blockade did not further increase the hypoxia caused by
VEGF blockade.
Combined notch and VEGF blockade disrupts tumor
vasculature
Combined blockade of VEGF and Notch reduced tumor
viability, but did not further increase tumor hypoxia. To
further understand the effect of combined blockade, wequantified tumor vasculature, using IHC for the base-
ment membrane marker collagen IV, which forms a peri-
vascular envelope that can persist after vascular
regression. We detected a ~50% increase in collagen IV
in NGP-LacZ + BV tumors as compared to both control
NGP-LacZ and NGP-N1D + BV (Figure 4B), which sug-
gested increased collagen IV contributed by coopted vas-
culature (Figure 4A, arrowheads). Notably, however, we
noted persistent collagen IV in necrotic areas for
Table 1 Hypoxia associated gene sets* are enriched in BV treated tumors compared with LacZ tumors
ENRICHED GENE SETS FOR N1D+BV TUMORS ENRICHED GENE SETS FOR LacZ+BV TUMORS
POSITIVELY ENRICHED GENE SETS ES NES FDR q-val POSITIVELY ENRICHED GENE SETS ES NES FDR q-val
NAME NAME
NIKOLSKY_BREAST_CANCER_17Q21_Q25_AMPLICON 0.600 2.850 0.000 XU_HGF_TARGETS_REPRESSED_BY_AKT1_DN 0.570 2.420 0.001
XU_HGF_TARGETS_REPRESSED_BY_AKT1_DN 0.640 2.510 0.000 SEMENZA_HIF1_TARGETS 0.660 2.340 0.001
REACTOME_PHASE_1_FUNCTIONALIZATION 0.810 2.260 0.005 SEIDEN_ONCOGENESIS_BY_MET 0.530 2.310 0.001
SEMENZA_HIF1_TARGETS 0.660 2.220 0.005 KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION 0.530 2.300 0.001
KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION 0.540 2.220 0.005 HARRIS_HYPOXIA 0.530 2.290 0.001
CUI_TCF21_TARGETS_DN 0.680 2.170 0.009 PRAMOONJAGO_SOX4_TARGETS_UP 0.580 2.260 0.002
HARRIS_HYPOXIA 0.530 2.140 0.013 HELLER_SILENCED_BY_METHYLATION_DN 0.480 2.160 0.011
NIKOLSKY_BREAST_CANCER_17Q11_Q21_AMPLICON 0.550 2.130 0.012 CUI_TCF21_TARGETS_DN 0.660 2.140 0.013
KEGG_DRUG_METABOLISM_CYTOCHROME_P450 0.560 2.120 0.014 REACTOME_RNA_POLYMERASE_I_PROMOTER_OPENING 0.560 2.140 0.011
KEGG_GRAFT_VERSUS_HOST_DISEASE 0.600 2.090 0.018 LIU_COMMON_CANCER_GENES 0.560 2.100 0.019
DAZARD_RESPONSE_TO_UV_SCC_UP 0.510 2.070 0.026 KEGG_SYSTEMIC_LUPUS_ERYTHEMATOSUS 0.460 2.080 0.022
LANDIS_BREAST_CANCER_PROGRESSION_UP 0.590 2.060 0.028 LEONARD_HYPOXIA 0.580 2.080 0.022
CHANNEL_REGULATOR_ACTIVITY 0.660 2.030 0.038 NOJIMA_SFRP2_TARGETS_UP 0.610 2.070 0.023
REACTOME_SYNTHESIS_OF_BILE_ACIDS_AND_BILE_SALTS 0.840 2.030 0.036 SPIRA_SMOKERS_LUNG_CANCER_DN 0.680 2.040 0.033
CYCLIC_NUCLEOTIDE_METABOLIC_PROCESS 0.840 2.010 0.044 RUNNE_GENDER_EFFECT_UP 0.830 2.020 0.042
SCHURINGA_STAT5A_TARGETS_UP 0.900 2.010 0.042 KEGG_LINOLEIC_ACID_METABOLISM 0.590 2.010 0.046
LU_TUMOR_ENDOTHELIAL_MARKERS_UP 0.700 2.000 0.044 NEBEN_AML_WITH_FLT3_OR_NRAS_DN 0.740 2.000 0.046
EXTRACELLULAR_LIGAND_GATED_ION_CHANNEL_ACTIVITY 0.660 1.990 0.047 LU_TUMOR_ENDOTHELIAL_MARKERS_UP 0.650 2.000 0.044
SEIDEN_ONCOGENESIS_BY_MET 0.500 1.990 0.046 NEGATIVELY ENRICHED GENE SETS
ELVIDGE_HIF1A_TARGETS_DN 0.480 1.980 0.045 NIKOLSKY_BREAST_CANCER_7P22_AMPLICON -0.820 -2.220 0.001
NEGATIVELY ENRICHED GENE SETS ENRICHED GENE SETS FOR N1D TUMORS
ELVIDGE_HIF1A_TARGETS_UP -0.610 -2.180 0.005 POSITIVELY ENRICHED GENE SETS
VANHARANTA_UTERINE_FIBROID_UP -0.650 -2.180 0.003 NAME ES NES FDR q-val
ELVIDGE_HYPOXIA_DN -0.520 -2.090 0.016 NIKOLSKY_BREAST_CANCER_17Q11_Q21_AMPLICON 0.640 2.290 0.002
DACOSTA_ERCC3_ALLELE_XPCS_VS_TTD_UP -0.710 -2.050 0.026 XU_HGF_TARGETS_REPRESSED_BY_AKT1_DN 0.610 2.240 0.004
NIKOLSKY_BREAST_CANCER_7P15_AMPLICON -0.860 -2.050 0.025 LASTOWSKA_NEUROBLASTOMA_COPY_NUMBER_UP 0.550 2.210 0.003















Table 1 Hypoxia associated gene sets* are enriched in BV treated tumors compared with LacZ tumors (Continued)
ELVIDGE_HIF1A_AND_HIF2A_TARGETS_UP -0.610 -2.000 0.045 CHANNEL_REGULATOR_ACTIVITY 0.720 2.080 0.020
ELVIDGE_HYPOXIA_BY_DMOG_DN -‐0.580 -‐1.980 0.048 AUXILIARY_TRANSPORT_PROTEIN_ACTIVITY 0.680 2.030 0.036
REACTOME_PHASE_1_FUNCTIONALIZATION 0.760 2.010 0.041
NEGATIVELY ENRICHED GENE SETS
GUENTHER_GROWTH_SPHERICAL_VS_ADHERENT_UP -0.850 -2.160 0.010
MATTIOLI_MULTIPLE_MYELOMA_SUBGROUPS -0.810 -2.070 0.040
MCGARVEY_SILENCED_BY_METHYLATION_IN_COLON_CANCE -0.680 -2.040 0.042
SCHLESINGER_METHYLATED_DE_NOVO_IN_CANCER -0.570 -2.020 0.041
We used gene set expression analysis (GSEA) to identify significantly enriched gene sets (FDR q-val <0.05) in N1D+BV, LacZ+BV, and N1D tumors, compared with LacZ tumors. *HYPOXIA RELATED GENE SETS:
ELVIDGE_HIF1A_TARGETS_DN (M2513) Genes down-regulated in MCF7 cells (breast cancer) after knockdown of HIF1A by RNAi; ELVIDGE_HIF1A_TARGETS_UP (M17905) Genes up-regulated in MCF7 cells (breast
cancer) after knockdown of HIF1A by RNAi; ELVIDGE_HIF1A_AND_HIF2A_TARGETS_UP (M7062) Genes up-regulated in MCF7 cells (breast cancer) after knockdown of both HIF1A and HIF2A by RNAi;
ELVIDGE_HYPOXIA_DN (M10175) Genes down-regulated in MCF7 cells (breast cancer) under hypoxia conditions; ELVIDGE_HYPOXIA_BY_DMOG_DN (M7030) Genes down-regulated in MCF7 cells (breast cancer)
treated with hypoxia mimetic DMOG; HARRIS_HYPOXIA (M10508) Genes known to be induced by hypoxia; LEONARD_HYPOXIA (M19622) Genes up-regulated in HK-2 cells kidney tubular epithelium under hypoxia















Figure 4 Combined Notch and VEGF blockaded disrupts tumor vasculature. (A) Immunofluorescence staining for Collagen IV (red)
demonstrated vasculature (arrows) in areas of necrosis (N) as indicated by absence of nuclei by DAPI (blue), for NGP-N1D and NGP-N1D + BV. For
clarity, a white dotted line delineates border between viable and necrotic tumor areas. In NGP-LacZ + BV arrowheads indicate coopted
glomeruli. Bar = 200 μm. (B) Collagen IV was quantified, with NGP-LacZ + BV significantly higher in comparison to NGP-LacZ and NGP-N1D + BV.
Error bars represent SD. *P < 0.05, **P < 0.01.
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areas denoted by “N” and delimited by dashed line).
These results suggest that Notch blockade disrupts
vasculature, with vascular regression marked by the
collagen IV sleeves at sites of previously functioning
vessels [7].
Notch and VEGF blockade additively decrease survival of
tumor endothelial cells
We assessed endothelial cells in vasculature by IHC for
PECAM-1 (Figure 5A). Combined VEGF and Notch block-
ade significantly decreased PECAM-1 staining (Figure 5B),
compared to NGP-LacZ (68%), NGP-N1D (46%), and
NGP-LacZ + BV (56%). These results along with the
decrease in branching seen in the lectin perfusion studies,
suggest that combined inhibition with NGP-N1D+ BV
decreases endothelial sprouting and neoangiogenesis.Previous studies have suggested that both Notch and
VEGF can act as survival signals for ECs. We therefore
hypothesized that combined blockade would result in in-
creased EC apoptosis. Quantification of apoptotic ECs
was done using TUNEL (Figure 5C, red), PECAM-1
(Figure 5C, green), and nuclear DAPI immunostaining
(Figure 5C, blue). A cell was considered an apoptotic EC
when its nucleus, stained by DAPI, overlapped with
TUNEL stain (red), and was surrounded by PECAM-1
(green) (Figure 5C, arrowheads). The number of apop-
totic ECs in each section was then normalized to the
PECAM positive area in each tumor. This quantifica-
tion showed a significant increase in apoptotic EC in
NGP-N1D + BV tumors (Figure 5D, P < 0.01). This in-
crease in apoptotic ECs suggested that Notch and
VEGF are both survival signals in tumor ECs, which
act independently.
Figure 5 Combined Notch and VEGF decreases endothelial cell coverage. (A) Representative pictures of PECAM-1 immunofluorescence (green)
of NGP-LacZ controls (upper left), NGP-N1D (upper right), NGP-LacZ + BV (lower left), and NGP-N1D + BV (lower right). Bar = 100 μm. (B) Quantification
of PECAM-1 immunofluorescence. NGP-N1D and NGP-LacZ + BV tumors had decreased PECAM-1 than NGP-LacZ controls. NGP-N1D + BV tumors had
an additive decrease in PECAM-1. Error bars represent SD. **P < 0.01, ***P < 0.001. (C) Representative pictures of triple staining for TUNEL (red),
PECAM-1 (green), DAPI (blue), white arrowheads. Bar = 25 μm (D) The number of DAPI(+), TUNEL(+) cells surrounded by PECAM-1 in each tumor
normalized by the viable area shows increased apoptotic ECs in NGP-N1D + BV tumors. Error bars represent SD. **P < 0.01. (E) HUVECs incubated with
N1D and BV had increased apoptosis compared to HUVECs with BV only. HUVECs incubated with N1D and VEGF had decreased apoptosis compared
to N1D with BV, but were not different from HUVEC incubated with BV only. Consistent with the known role of VEGF promoting endothelial cell
survival, HUVEC incubated with VEGF had lower apoptotic levels than HUVECs incubated with BV, and lower apoptotic levels than HUVECs incubated
with N1D and VEGF. Error bars represent SD. *P < 0.05. (F) N1D with BV resulted in increased BrdU incorporation by HUVECs compared to BV only.
Addition of VEGF did not affect N1D-induced proliferation. Error bars represent SD. *P < 0.05.
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survival in vitro, we used human umbilical vein endothe-
lial cells (HUVEC). Conditioned media (CM) from
NGP-N1D cells was collected as a source of N1D, with
CM from NGP-LacZ as a control. CM from NGP-LacZ
and NGP-N1D contained similar amounts of VEGF(1.26 ± 0.79 vs. 1.28 ± 1.4 ng/ml, respectively, P = n.s.).
We therefore added 50 ng/ml of BV to block the VEGF
that was present in the CM. We incubated the HUVECs
in CM + BV or CM +VEGF (20 ng/ml of rhVEGF165)
for 23 hrs and quantified apoptosis using a cell death
ELISA. HUVECs incubated with N1D CM+ BV had 1.5
Hernandez et al. Vascular Cell 2013, 5:17 Page 11 of 14
http://www.vascularcell.com/content/5/1/17to 2 fold higher apoptosis levels than HUVECs incu-
bated with control CM + BV (Figure 5E). HUVEC apop-
tosis was significantly reduced when VEGF was added to
the CM containing N1D (Figure 5E).
Inhibition of Notch signaling with γ-secretase inhibi-
tors or anti-Dll4 antibodies have found that there is in-
creased EC proliferation in vitro [8], while Notch1
activation leads to endothelial cell cycle arrest [9]. Using
conditioned medium from NGP-LacZ or NGP-N1D
cells, with either 50 ng/ml BV or 20 ng/ml rhVEGF165,
we found that N1D caused a small increase (9%) in
HUVEC proliferation in vitro, and which was not af-
fected by addition of VEGF (10%, Figure 5F). Together,
these data suggest that both endothelial proliferation
and apoptosis increase simultaneously in NGP-N1D, as
compared to NGP-LacZ tumors. ECs in NGP-N1D tu-
mors treated with BV, proliferate more than controls,Figure 6 Notch blockade disrupts pericyte interaction with endotheli
(red). NGP-N1D pericytes are discontinuous and their morphology is altered
BV vasculature had continuous coverage of pericytes. Pericytes of NGP-N1
right, arrows). RBCs autofluoresce green. Bar = 50 μm. (B) Quantification
decrease in NGP-LacZ + BV and NGP-N1D + BV. Error bars represent SD.
PECAM-1 (red) and αSMA (green). NGP-LacZ control tumors demonstrated
NGP-Notch1 decoy tumors had stretches of PECAM-1(+) cells without sur
tumors had PECAM-1(+) cells surrounded by thin layers of αSMA(+) peri
cells not surrounded by αSMA(+) pericytes (lower right, arrowhead). RBCs abut also display more EC apoptosis than either N1D or
BV treatment alone.
Notch1 decoy and BV alter pericyte coverage of blood
vessels
Immunostaining for the mature pericyte marker αSMA
demonstrated discontinuity in this stromal cell envelope
in NGP-N1D tumors as compared to NGP-LacZ, along
with a more flattened morphology (Figure 6A, arrows),
in agreement with our previous data [5]. BV treatment
led to a thinner layer of pericytes, although immuno-
staining revealed a continuous pattern (Figure 6A, bot-
tom left). Combined inhibition with N1D + BV, similar
to N1D, led to discontinuity together with altered
pericyte morphology (Figure 6A, right panels, white ar-
rows). Quantification revealed an increase in total
αSMA(+) area in NGP-N1D compared to the otheral cells. (A) Immunofluorescence for the mature pericyte marker αSMA
(right top, white arrows), compared to controls (left top). NGP-LacZ +
D + BV tumors showed discontinuity and altered morphology (bottom
of αSMA showed significant increase in NGP-N1D tumors, with a
**P < 0.01, ***P < 0.001. (C) Confocal analysis of immunostaining for
PECAM-1(+) cells surrounded by αSMA(+) pericytes (upper left, arrows),
rounding αSMA(+) pericytes (upper right, arrowheads). NGP-LacZ + BV
cytes (lower left, arrow), while NGP-N1D + BV tumors had PECAM-1(+)
re pseudocolored grey.
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αSMA(+) area compared to NGP-LacZ and NGP-N1D,
indicating that combined blockade both diminishes the
amount of pericytes coverage as well as disrupting the
coverage (Figure 6B). Similar findings were seen using
NG2, a marker of more immature pericytes (data not
shown).
Confocal imaging for endothelial marker PECAM-1
and αSMA revealed that, while NGP-LacZ controlFigure 7 Silencing of Notch1 does not recapitulate the vasculature se
not different. Error bars represent SD. (B) The number of TUNEL positive
Cleaved Notch1 is present in vasculature of NGP-EV and NGP-shN1 (arrow
coverage in vasculature of NGP-shN1 tumors. Bar = 100 μm. (E) The perce
shN1 tumors. Error bars represent SD. P = n.s. (F) The pericyte marker αSM
tumors. Bar = 100 μm. (G) There was no difference in percentage of αSMA
SD. P = n.s.tumor EC had neighboring pericytes (arrows), NGP-
N1D tumors developed segments of ECs that lacked
pericyte coverage (Figure 6C, right panel, arrowheads).
NGP-LacZ + BV tumors contained ECs still covered
by pericytes, although the pericyte layer was thinned
compared to controls (Figure 6C, lower left panel).
Similar to the NGP-N1D tumor vessels, NGP-N1D+ BV
vessels displayed segmental defects in pericyte coverage
(Figure 6C, lower right, white arrows).en with NGP-N1D. (A) NGP-EV and NGP-shN1 tumor weights were
cells is not different between the NGP-EV and NGP-shN1 tumors. (C)
s). (D) The EC marker PECAM-1 does not show discontinuity or lack of
ntage of PECAM-1 coverage did not differ between NGP-EV and NGP-
A does not show erratic, discontinuous immunostaining in NGP-shN1
coverage between NGP-EV and NGP-shN1 tumors. Error bars represent
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Immunofluorescence for cleaved Notch1 demonstrated
Notch activation in vasculature of NGP-LacZ and NGP-
LacZ + BV, but a paucity of activation in NGP-N1D and
NGP-N1D + BV tumor vessels (Additional file 3). These
data suggest that Notch blockade predominantly affects
vascular cells. However, quantitative real time PCR ana-
lysis revealed that NGP tumor cells also express Notch1.
In order to test the specificity of the effects of Notch
blockade, we silenced Notch1 (shN1) in NGP. In vitro,
NGP-shN1 had a 70% decrease in Hes1 and 50% decrease
in Hey1 mRNA compared to empty vector (NGP-EV). In
vitro, NGP-EV and NGP-shN1 cells proliferated at com-
parable rates, assessed by MTT assay (P = n.s.). We im-
planted the NGP-EV and NGP-shN1 cells into athymic
mice and analyzed the tumors 6 weeks after implantation.
We confirmed a 78 ± 18% (P < 0.05) reduction of Notch1
mRNA, as well as reduction in expression of the Notch
downstream target gene Hes1 by 90% (P = 0.04), in NGP-
shNotch1 as compared to NGP-EV. We found no changes
in tumor weight (Figure 7A), or apoptosis (Figure 7B) as a
result of silencing Notch1. Immunostaining revealed that
shN1 did not affect Notch1 activation in the tumor blood
vessels (Figure 7C). The vasculature as assessed by per-
centage of PECAM-1 and αSMA positive area IHC,
was similar in NGP-shNotch1 tumors compared to
control NGP-EV tumors (Figure 7D-G). Lastly, the vas-
culature in NGP-shN1 tumors did not appear to be
disrupted (Figure 7E,F), as was seen with Notch blockade
(Figure 6A). Together, these data support the notion that
the effects of N1D are due to Notch blockade in the tumor
vasculature, rather than to an effect on the tumor cells.
Discussion
A growing body of literature demonstrates crosstalk be-
tween Notch and VEGF pathways in angiogenesis
in vitro [10-13], as well as in the mouse retina model
[5,8,14,15]. The interaction between Notch and VEGF in
tumor angiogenesis, however, is still in the process of
definition. Our data suggests that Notch and VEGF have
independent but coordinated functions in tumor angio-
genesis, leading to additive effects when both pathways
are simultaneously inhibited. VEGF blockade limits ini-
tial vessel sprouting and branching, and then later pro-
motes vascular cooption [2] and the recruitment of
pericytes that can stabilize the vasculature in the absence
of VEGF [16,17]. Our results demonstrate that Notch
blockade inhibits the later processes of cooption and
EC/pericyte interaction.
Our data indicate that while VEGF blockade induces
vascular cooption, this does not rescue tumors from
hypoxia. Furthermore, while Notch blockade decreases
cooption, this does not increase the VEGF-blockade in-
duced hypoxia. This suggests that vascular cooption isrelatively inefficient as a mechanism of providing oxygen
to tumors; other potential contributions of co-opted ves-
sels to tumor homeostasis remain unclear.
Our current results demonstrate that while Notch
blockade can disrupt EC/pericyte interaction, it is only
in the absence of VEGF that there is marked loss of vas-
culature, perfusion, and subsequent induction of tumor
necrosis. In the context of loss of VEGF, Notch blockade
causes EC apoptosis both in vitro and in vivo. This sug-
gests that VEGF can rescue ECs when Notch is blocked.
Other groups have shown that antibodies against Dll4
and Notch1 increase non-functional EC vasculature
in subcutaneous tumor models [8,14,15]. Endothelial
Jagged1, however, has been shown to decrease sprouting
in the mouse retinal model [18]. Therefore, the ability of
the N1D to block both signaling by both Dll4 and
Jagged1 [5] may explain the observed decrease in EC in
NGP-N1D tumors. Our studies also suggest that the
effect of Notch blockade on tumor angiogenesis is
context-dependent. Thus, this effect may vary with dif-
ferent tumor models, and perhaps with tumor types.
Conclusions
Our data lead us to propose that the Notch and VEGF
pathways play distinct but complementary roles in
tumor angiogenesis, and that Notch is required for
VEGF-mediated vascular remodeling. Here we show that
concurrent blockade disrupts primary tumor vasculature
and viability further than inhibition of either pathway
alone, and that manipulation of each pathway is
reflected in distinct vascular defects. Further investiga-
tion of the interaction between VEGF and Notch signa-
ling in vasculature may allow refinement of a combined
approach to targeting tumor angiogenesis.
Additional files
Additional file 1: Figure S1. N1D is expressed in NGP-N1D and NGP-
N1D + BV tumors. A) Immunostaining for human Fc indicates the presence
of N1D in NGP-N1D tumors (right panel, red), but not in NGP-LacZ tumors
(left panel). Bar = 200 μm B) SDS-Page shows the presence of N1D (upper
band) in NGP-N1D + BV, but not in NGPLacZ + BV tumors. Presence of BV,
which also contains Fc, is observed in both NGP-LacZ + BV and NGP-N1D+ BV
tumors (lower band).
Additional file 2: Figure S2. Cleaved Notch1 activity is decreased in
N1D tumors. Immunostaining for cleaved Notch1 (red) demonstrates
increased Notch1 activity in vasculature of NGP-LacZ and NGP-LacZ + BV
tumors, but nearly absent Notch1 activity in NGP-N1D and NGP-N1D + BV
tumors. For NGP-LacZ + BV, cleaved Notch1 is seen in vascular cells
surrounding a coopted glomeruli (green fluorescence due to fluorescein-
labeled lectin). RBCs autofluoresce green/yellow. Nuclei are stained with
DAPI (blue). Bar = 50 μm.
Additional file 3: Genes up/down regulated in NGP-N1D+BV, NGP-
N1D, NGP-LacZ+BV tumors.
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